Glaucoma gene therapy

Expert Review of Ophthalmology

Volumn 2, Issue 2, 2007, Pages 227-236

  Liu, Xuyang ^a   Brandt, Curtis R ^b   Rasmussen, Carol A ^c   Kaufman, Paul L ^d  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Health   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

gene therapy; glaucoma

Indexed keywords

EID: 36849086178     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.2.227     Document Type: Article

References (91)

1. Hauswirth WW, Beaufrere L. Ocular gene therapy: quo vadis? Invest. Ophthalmol. Vis. Sci. 41 (10), 2821–2826 (2000).
2. Tian B, Geiger B, Epstein DL et al. Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest. Ophthalmol. Vis. Sci. 41 (3), 619–623 (2000).
3. Fautsch MP, Bahler CK, Vrabel AM et al. Perfusion of his-tagged eukaryotic myocilin increases outflow resistance in human anterior segments in the presence of aqueous humor. Invest. Ophthalmol. Vis. Sci. 47 (1), 213–221 (2006).
4. Fautsch MP, Vrabel AM, Johnson DH. Characterization of the Felix domesticus (cat) glaucoma-associated protein myocilin. Exp. Eye Res. 82 (6), 1037–1045 (2006).
5. Vittitow JL, Garg R, Rowlette LL et al. Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol. Vis. 8 (3), 32–44 (2002).
6. Rao PV, Deng P, Maddala R et al. Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow. Mol. Vis. 11 (4), 288–297 (2005).
7. Aktories K, Mohr C, Koch G. Clostridium botulinum C3 ADP-ribosyltransferase. Curr. Top. Microbiol. Immunol. 175, 115–131 (1992).
8. Liu X, Hu Y, Filla MS et al. The effect of C3 transgene expression on actin and cell adhesions in cultured HTM cells and on outflow facility in organ cultured monkey eyes. Mol. Vis. 11 (12), 1112–1121 (2005).
9. Huber PA. Caldesmon. Int. J. Biochem. Cell Biol. 29 (8–9), 1047–1051 (1997).
10. Grosheva I, Vittitow JL, Goichberg P et al. Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells. Exp. Eye Res. 82 (6), 945–958 (2006).
11. Gabelt BT, Hu Y, Vittitow JL et al. Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. Exp. Eye Res. 82 (6), 935–944 (2006).
12. Ronkko S, Rekonen P, Kaarniranta K et al. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. DOI: 10.1007/s00417-006-0440-1 (2006) (Epub ahead of print).
13. Khurana RN, Deng PF, Epstein DL et al. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp. Eye Res. 76 (1), 39–47 (2003).
14. Kee C, Sohn S, Hwang JM. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest. Ophthalmol. Vis. Sci. 42 (12), 2856–2860 (2001).
15. Hudde T, Apitz J, Bordes-Alonso R et al. Gene transfer to trabecular meshwork endothelium via direct injection into the Schlemm canal and in vivo toxicity study. Curr. Eye Res. 30 (12), 1051–1059 (2005).
16. Toris CB, Yablonski ME, Wang YL et al. Aqueous humor dynamics in the aging human eye. Am. J. Ophthalmol. 127 (4), 407–412 (1999).
17. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog. Retin. Eye Res. 24 (5), 612–637 (2005).
18. Toris CB, Koepsell SA, Yablonski ME et al. Aqueous humor dynamics in ocular hypertensive patients. J. Glaucoma 11 (3), 253–258 (2002).
19. Oh DJ, Martin JL, Williams AJ et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest. Ophthalmol. Vis. Sci. 47 (3), 953–963 (2006).
20. Marshall B, Keskin DB, Mellor AL. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem. 2 (5), 5 (2001).
21. Ota T, Aihara M, Narumiya S et al. The effects of prostaglandin analoques on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 46 (11), 4159–4163 (2005).
22. Barraza RA, McLaren J, Poeschla EM. COX-2 pathway gene therapy for glaucoma: sustained IOP reduction with integrated prostaglandin biosynthesis and response transgenes. ARVO Annual Meeting. Ft Lauderdale, FL, USA, May 6–10, 2007.
23. Liu X, Brandt CR, Gabelt BT et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp. Eye Res. 69 (4), 385–395 (1999).
24. Pintor JJ, Mediero A, Jimenez A et al. siRNA in the treatment of ocular hypertension targeting α and β adrenoceptors. ARVO Annual Meeting. Ft Lauderdale, FL, USA, April 30–May 4, 2006.
25. Jimenez A, Sesto A, Pintor J et al. RNAi: a new strategy for treating ocular hypertension silencing carbonic anhydrases. ARVO Annual Meeting. Ft Lauderdale, FL, USA, April 30–May 4, 2006.
26. Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol. Clin. North Am. 18 (4), 585–596 (2005).
27. Peinado-Ramón P, Salvador M, Villegas-Pérez MP et al. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells: a quantitative in vivo study. Invest. Ophthalmol. Vis. Sci. 37 (4), 489–500 (1996).
28. Klöcker N, Bräunling F, Isenmann S et al. In vivo neurotrophic effects of GDNF on axotomized retinal ganglion cells. Neuroreport 8 (16), 3439–3442 (1997).
29. Mey J, Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res. 602 (2), 304–317 (1993).
30. Di Polo A, Aigner LJ, Dunn RJ et al. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc. Natl Acad. Sci. USA 95 (7), 3978–3983 (1998).
31. Martin KR, Quigley HA, Zack DJ et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44 (10), 4357–4365 (2003).
32. Pernet V, Hauswirth WW, Di Polo A. Extracellular signal-regulated kinase 1/2 mediates survival, but not axon regeneration, of adult injured central nervous system neurons in vivo. J. Neurochem. 93 (1), 72–83 (2005).
33. Zhou Y, Pernet V, Hauswirth WW et al. Activation of the extracellular signal-regulated kinase 1/2 pathway by AAV gene transfer protects retinal ganglion cells in glaucoma. Mol. Ther. 12 (3), 402–412 (2005).
34. Weise J, Isenmann S, Klocker N et al. Adenovirus-mediated expression of ciliary neurotrophic factor (CNTF) rescues axotomized rat retinal ganglion cells but does not support axonal regeneration in vivo. Neurobiol. Dis. 7 (3), 212–223 (2000).
35. Weise J, Ankerhold R, Bahr M. Degeneration and regeneration of ganglion cell axons. Microsc. Res. Tech. 48 (2), 55–62 (2000).
36. Martinou JC, Dubois-Dauphin M, Staple JK et al. Overexpression of Bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 13 (4), 1017–1030 (1994).
37. Malik JM, Shevtsova Z, Bahr M et al. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol. Ther. 11 (3), 373–381 (2005).
38. Mckinnon SJ, Lehman DM, Tahzib NG et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol. Ther. 5 (6), 780–787 (2002).
39. Tahzib NG, Ransom NL, Reitsamer HA et al. α-fodrin is cleaved by caspase-3 in a chronic ocular hypertensive (COH) rat model of glaucoma. Brain Res. Bull. 62 (6), 491–495 (2004).
40. Renwick J, Narang MA, Coupland SG et al. XIAP-mediated neuroprotection in retinal ischemia. Gene Ther. 13 (4), 339–347 (2006).
41. Campochiaro PA. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene 13 (6), 559–562 (2006).
42. Lingor P, Koeberle P, Kugler S et al. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death. Brain 128 (Pt 3), 550–558 (2005).
43. Perkins TW, Faha B, Ni M et al. Adenovirus-mediated gene therapy using human p21WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch. Ophthalmol. 120 (7), 941–949 (2002).
44. Wen SF, Chen Z, Nery J et al. Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp. Eye Res. 77 (3), 355–365 (2003).
45. Heatley G, Kiland J, Faha B et al. Gene therapy using p21WAF-1/Cip-1 to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension. Gene Ther. 11 (12), 949–955 (2004).
46. Mamiya K, Ohguro H, Ohguro I et al. Effects of matrix metalloproteinase-3 gene transfer by electroporation in glaucoma filter surgery. Exp. Eye Res. 79 (3), 405–410 (2004).
47. Borrás T. Recent developments in ocular gene therapy. Exp. Eye Res. 76 (3), 643–652 (2003).
48. Andrieu-Soler C, Bejjani RA, de Bizemont T et al. Ocular gene therapy: a review of nonviral strategies. Mol. Vis. 12, 1334–1347 (2006).
49. Hangai M, Tanihara H, Honda Y et al. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest. Ophthalmol. Vis. Sci. 39 (3), 509–516 (1998).
50. Wheeler CJ, Felgner PL, Tsai YJ et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc. Natl Acad. Sci. USA 93 (21), 11454–11459 (1996).
51. Ferrari ME, Rusalov D, Jnas J et al. Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes. Nucleic. Acids Res. 30 (8), 1808–1816 (2002).
52. Zabner J, Fasbender AJ, Moninger T et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 270 (32), 18997–19007 (1995).
53. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim. Biophys. Acta 1235 (2), 296–304 (1995).
54. Pramfalk C, Lanner J, Andersson M et al. Insulin receptor activation and down-regulation by cationic lipid transfection reagents. BMC Cell. Biol. 5, 7 (2004).
55. Liu G, Li D, Pasumarthy MK et al. Nanoparticles of compacted DNA transfect postmitotic cells. J. Biol. Chem. 278 (35), 32578–32586 (2003).
56. Farjo R. Skaggs J, Quiambao AB et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PloS ONE 1 (1), e38 (2006).
57. Sakai H, Park BC, Shen X et al. Transduction of TAT fusion proteins into the human and bovine trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 47 (10), 4427–4434 (2006).
58. Harbour JW, Worley L, Ma D et al. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol. 120 (10), 1341–1346 (2002).
59. Uherek C, Wels W. DNA-carrier proteins for targeted gene delivery. Adv. Drug Deliv. Rev. 44 (2–3), 153–166 (2000).
60. Wagner E. Strategies to improve DNA polyplexes for in vivo gene transfer: will “artificial viruses” be the answer? Pharm. Res. 21 (1), 8–14 (2004).
61. Budenz DL, Bennett J, Alonso L et al. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 36 (11), 2211–2215 (1995).
62. Andrawiss M, Maron A, Beltran W et al. Adenovirus-mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma. J. Gene. Med. 3 (3), 228–239 (2001)
63. Clark AF, Millar C, Pang I-H et al. Adenoviral gene transfer of active human transforming growth factor-2 induces elevated intraocular pressure in rats. ARVO Annual Meeting. Ft Lauderdale, FL, USA, April 30–May 4, 2006.
64. Yang Y, Nunes FA, Berencsi K et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci USA 91 (10), 4407–4411 (1994).
65. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. 133 (1), 9–29 (2006).
66. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J. Neurosci. Methods 98 (2), 95–104 (2000).
67. Dudus L, Anand V, Acland GM et al. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res. 39 (15), 2545–2553 (1999).
68. Guy J, Qi X, Muzyczka N et al. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch. Ophthalmol. 117 (7), 929–937 (1999).
69. Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors. Methods 28 (2), 267–275 (2002).
70. Folliot S, Briot D, Conrath H et al. Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. J. Gene Med. 5 (6), 493–501 (2003).
71. Schuettauf F, Vorwerk C, Naskar R et al. Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr. Eye Res. 29 (6), 379–386 (2004).
72. Smith AJ, Schlichtenbrede FC, Tschernutter M et al. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol. Ther. 8 (2), 188–195 (2003).
73. Narfstrom K, Bragadottir R, Redmond TM et al. Functional and structural evaluation after AAV. RPE65 gene transfer in the canine model of Leber’s congenital amaurosis. Adv. Exp. Med. Biol. 533, 423–430 (2003).
74. Hernandez YJ, Wang J, Kearns WG et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73 (10), 8549–8558 (1999).
75. Borrás T, Xue W, Choi VW et al. Mechanisms of AAV transduction in glaucoma-associated human trabecular meshwork cells. J. Gene Med. 8 (5), 589–602 (2006).
76. Loewen N, Bahler C, Teo WL et al. Preservation of aqueous outflow facility after second-generation FIV vector-mediated expression of marker genes in anterior segments of human eyes. Invest. Ophthalmol. Vis. Sci. 43 (12), 3686–3690 (2002).
77. Loewen N, Fautsch MP, Teo WL et al. Long-term, targeted genetic modification of the aqueous humor outflow tract coupled with noninvasive imaging of gene expression in vivo. Invest. Ophthalmol. Vis. Sci. 45 (9), 3091–3098 (2004).
78. Poeschla EM, Loewen N, Rasmussen C et al. Transduction of nonhuman primate trabecular meshwork with lentiviral vectors. ARVO Annual Meeting. Ft Lauderdale, FL, USA, April 30–May 4, 2006.
79. Zerbini LF, Libermann TA, Ventura AM. Insertion of an exogenous domain in the adenovirus type 2 fiber globular region. Biochem. Biophys. Res. Commun. 296 (4), 897–903 (2002).
80. Gonzalez P, Epstein DL, Borrás T. Characterization of gene expression in human trabecular meshwork using single-pass sequencing of 1060 clones. Invest. Ophthalmol. Vis. Sci. 41 (12), 3678–3693 (2000).
81. Tomarev SI, Wistow G, Raymond V et al. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest. Ophthalmol. Vis. Sci. 44 (6), 2588–2596 (2003).
82. Gonzalez P, Caballero M, Liton PB et al. Expression analysis of the matrix GLA protein and VE-cadherin gene promoters in the outflow pathway. Invest. Ophthalmol. Vis. Sci. 45 (5), 1389–1395 (2004).
83. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem. J. 365, 119–126 (2002).
84. De Ceuninck F, Gaufillier S, Bonnaud A et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem. Biophys. Res. Commun. 285, 926–931 (2001).
85. Liton PB, Liu X, Stamer WD et al. Specific targeting of gene expression to a subset of human trabecular meshwork cells using the chitinase 3-like 1 promoter. Invest. Ophthalmol. Vis. Sci. 46 (1), 183–190 (2005).
86. Acland GM, Aguirre GD, Ray J et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28 (1), 92–95 (2001).
87. Fischer D, Bieber T, Li YX et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16 (8), 1273–1279 (1999).
88. Florea BI, Meaney C, Junginger HE et al. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated Cos-1 cell cultures. AAPS Pharm. Sci. 4, E12 (2002).
89. Fischer D, von Harpe A, Kunath K et al. Copolymers of ethylene imine and N-(2-hydroxyethyl)-ethylene imine as tools to study effects of polymer structure on physicochemical and biological properties of DNA complexes. Bioconjug. Chem. 13 (5), 1124–1133 (2002).
90. Gerdes CA, Castro MG, Lowenstein PR. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol. Ther. 2 (4), 330–338 (2000).
91. De Geest B, Linthout SV, Lox M et al. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum. Gene Ther. 11 (1), 101–112 (2000).